Cargando…

Discontinuation of reimbursement of benzodiazepines in the Netherlands: does it make a difference?

BACKGROUND: In an attempt to control chronic benzodiazepine use and its costs in the Netherlands, health care insurance reimbursement of this medication was stopped on January 1(st) 2009. This study investigates whether benzodiazepine prescriptions issued by general practitioners changed during the...

Descripción completa

Detalles Bibliográficos
Autores principales: Kollen, Boudewijn J, van der Veen, Willem Jan, Groenhof, Feikje, Donker, Gé A, van der Meer, Klaas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3534512/
https://www.ncbi.nlm.nih.gov/pubmed/23170874
http://dx.doi.org/10.1186/1471-2296-13-111
_version_ 1782475344834461696
author Kollen, Boudewijn J
van der Veen, Willem Jan
Groenhof, Feikje
Donker, Gé A
van der Meer, Klaas
author_facet Kollen, Boudewijn J
van der Veen, Willem Jan
Groenhof, Feikje
Donker, Gé A
van der Meer, Klaas
author_sort Kollen, Boudewijn J
collection PubMed
description BACKGROUND: In an attempt to control chronic benzodiazepine use and its costs in the Netherlands, health care insurance reimbursement of this medication was stopped on January 1(st) 2009. This study investigates whether benzodiazepine prescriptions issued by general practitioners changed during the first two years following implementation of this regulation. METHODS: Registry study based on data from all benzodiazepine users derived from the Registration Network Groningen. This general practice-based research network collects longitudinal data on the primary care administered to about 30,000 patients. Based on the number of quarterly accumulated prescription days, a comparison was made of benzodiazepine prescriptions issued between 2007/2008 and 2009/2010. Also investigated was which type of user (i.e. short-term or long-term) showed the most change. RESULTS: Information on benzodiazepine prescriptions among 5,200 patients from 16 consecutive trimesters between 2007 and 2010 was available for analysis. A significant reduction in prescription days was observed between 2007/2008 and 2009/2010. Overall, an estimated 1.73 (CI:-1.94 to -1.53; p<0.001) days were less prescribed per trimester after the termination of reimbursement. In particular, short-term users experienced a reduction in prescription days in 2009 and 2010. The number of long-term users decreased by 2.3%, while the number of individuals that did not use increased by 4.2%. CONCLUSIONS: A total reduction of almost 14 prescription days was observed over eight trimesters after implementation of the regulation to terminate the reimbursement of benzodiazepines. Short-term users were mainly responsible for this reduction in prescription days in 2009 and 2010. Although long-term users did not alter their benzodiazepine use in 2009 and 2010, the number of long-term users decreased slightly.
format Online
Article
Text
id pubmed-3534512
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35345122013-01-03 Discontinuation of reimbursement of benzodiazepines in the Netherlands: does it make a difference? Kollen, Boudewijn J van der Veen, Willem Jan Groenhof, Feikje Donker, Gé A van der Meer, Klaas BMC Fam Pract Research Article BACKGROUND: In an attempt to control chronic benzodiazepine use and its costs in the Netherlands, health care insurance reimbursement of this medication was stopped on January 1(st) 2009. This study investigates whether benzodiazepine prescriptions issued by general practitioners changed during the first two years following implementation of this regulation. METHODS: Registry study based on data from all benzodiazepine users derived from the Registration Network Groningen. This general practice-based research network collects longitudinal data on the primary care administered to about 30,000 patients. Based on the number of quarterly accumulated prescription days, a comparison was made of benzodiazepine prescriptions issued between 2007/2008 and 2009/2010. Also investigated was which type of user (i.e. short-term or long-term) showed the most change. RESULTS: Information on benzodiazepine prescriptions among 5,200 patients from 16 consecutive trimesters between 2007 and 2010 was available for analysis. A significant reduction in prescription days was observed between 2007/2008 and 2009/2010. Overall, an estimated 1.73 (CI:-1.94 to -1.53; p<0.001) days were less prescribed per trimester after the termination of reimbursement. In particular, short-term users experienced a reduction in prescription days in 2009 and 2010. The number of long-term users decreased by 2.3%, while the number of individuals that did not use increased by 4.2%. CONCLUSIONS: A total reduction of almost 14 prescription days was observed over eight trimesters after implementation of the regulation to terminate the reimbursement of benzodiazepines. Short-term users were mainly responsible for this reduction in prescription days in 2009 and 2010. Although long-term users did not alter their benzodiazepine use in 2009 and 2010, the number of long-term users decreased slightly. BioMed Central 2012-11-21 /pmc/articles/PMC3534512/ /pubmed/23170874 http://dx.doi.org/10.1186/1471-2296-13-111 Text en Copyright ©2012 Kollen et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Kollen, Boudewijn J
van der Veen, Willem Jan
Groenhof, Feikje
Donker, Gé A
van der Meer, Klaas
Discontinuation of reimbursement of benzodiazepines in the Netherlands: does it make a difference?
title Discontinuation of reimbursement of benzodiazepines in the Netherlands: does it make a difference?
title_full Discontinuation of reimbursement of benzodiazepines in the Netherlands: does it make a difference?
title_fullStr Discontinuation of reimbursement of benzodiazepines in the Netherlands: does it make a difference?
title_full_unstemmed Discontinuation of reimbursement of benzodiazepines in the Netherlands: does it make a difference?
title_short Discontinuation of reimbursement of benzodiazepines in the Netherlands: does it make a difference?
title_sort discontinuation of reimbursement of benzodiazepines in the netherlands: does it make a difference?
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3534512/
https://www.ncbi.nlm.nih.gov/pubmed/23170874
http://dx.doi.org/10.1186/1471-2296-13-111
work_keys_str_mv AT kollenboudewijnj discontinuationofreimbursementofbenzodiazepinesinthenetherlandsdoesitmakeadifference
AT vanderveenwillemjan discontinuationofreimbursementofbenzodiazepinesinthenetherlandsdoesitmakeadifference
AT groenhoffeikje discontinuationofreimbursementofbenzodiazepinesinthenetherlandsdoesitmakeadifference
AT donkergea discontinuationofreimbursementofbenzodiazepinesinthenetherlandsdoesitmakeadifference
AT vandermeerklaas discontinuationofreimbursementofbenzodiazepinesinthenetherlandsdoesitmakeadifference